{"id":3326,"date":"2021-07-16T05:42:44","date_gmt":"2021-07-16T05:42:44","guid":{"rendered":"http:\/\/deepfda.com\/?page_id=3326"},"modified":"2024-11-11T22:39:23","modified_gmt":"2024-11-11T22:39:23","slug":"%e5%9f%ba%e5%9b%a0%e6%b2%bb%e7%96%97%e4%b8%b4%e5%ba%8a%e5%89%8d%e7%a0%94%e7%a9%b6","status":"publish","type":"page","link":"https:\/\/deepfda.com\/us\/%e5%9f%ba%e5%9b%a0%e6%b2%bb%e7%96%97%e4%b8%b4%e5%ba%8a%e5%89%8d%e7%a0%94%e7%a9%b6\/","title":{"rendered":"Preclinical Research On Gene Therapy"},"content":{"rendered":"

<\/div><\/div><\/div>
<\/div>

Preclinical Research On Gene Therapy<\/span><\/span><\/h2>
We provide compliant preclinical research services for gene therapy to support candidate drugs in meeting regulatory requirements.<\/div><\/header>
<\/div>
<\/p>\n

The regulatory guidelines for the toxicology and safety pharmacology studies necessary for advancing gene therapy into human clinical trials are continuously evolving. Unlike other therapeutic categories, such as small molecules or biologics, the preclinical research requirements for gene therapy are tailored to the specific characteristics of the therapy. Furthermore, gene therapy encompasses a variety of approaches, including in vitro gene editing and in vivo viral and non-viral vector therapies.<\/p>\n

\n<\/div>

<\/div>
<\/p>\n

Types of gene therapy vectors include:<\/p>\n